Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Keryx Reports Positive Midstage Safety Results For Kidney Disease Drug Zerenex

By Pharmaceutical Processing | June 8, 2009

NEW YORK (AP) — Shares of Keryx Biopharmaceuticals Inc. jumped Monday after the company reported positive midstage safety results for its kidney disease drug. The stock rose 34 cents, or 31.6 percent, to $1.42 in morning trading. Shares earlier reached $1.58, their highest point in the past 52 weeks. The company is developing Zerenex as a treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage kidney disease. Those patients are on hemodialysis, which is used to remove waste products from the blood. The drug candidate met its key safety goals in the study. Meanwhile, the midstage study results suggested that the drug is effective in regulating serum phosphorous levels, though the study is not designed to test for effectiveness. Keryx is now in the process of developing a late-stage development program for the drug and is consulting with the FDA. The regulatory agency has already said the current studies are adequate to support late-stage clinical trials.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE